Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Shiv K. Gupta, Emily J. Smith, Ann C. Mladek, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen, Michael Weller, Eudocia Q. Lee, et al.
Neuro-Oncology (2020) Vol. 22, Iss. 8, pp. 1073-1113
Open Access | Times Cited: 840
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wei Wu, Jessica Klockow, Michael Zhang, et al.
Pharmacological Research (2021) Vol. 171, pp. 105780-105780
Open Access | Times Cited: 458
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 407
Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment
Belén Delgado-Martín, Miguel Ángel Medina
Advanced Science (2020) Vol. 7, Iss. 9
Open Access | Times Cited: 143
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana M. Neophytou, Ana Čipak Gašparović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14672-14672
Open Access | Times Cited: 81
Glioblastoma Therapy: Past, Present and Future
Elena Obrador, Paz Moreno-Murciano, María Oriol‐Caballo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2529-2529
Open Access | Times Cited: 64
Lower Grade Gliomas
Gilbert Youssef, Julie J. Miller
Current Neurology and Neuroscience Reports (2020) Vol. 20, Iss. 7
Open Access | Times Cited: 100
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma
Shaofang Wu, Xiaolong Li, Feng Gao, et al.
Neuro-Oncology (2021) Vol. 23, Iss. 6, pp. 920-931
Open Access | Times Cited: 94
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study
Hao‐Wen Sim, Kerrie L. McDonald, Zarnie Lwin, et al.
Neuro-Oncology (2021) Vol. 23, Iss. 10, pp. 1736-1749
Open Access | Times Cited: 62
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma
Alessandra Ferri, Venturina Stagni, Daniela Barilà
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 4910-4910
Open Access | Times Cited: 60
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale
Daranjit Sandhu, Albert A. Antolín, Anthony R. Cox, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 742-752
Open Access | Times Cited: 54
Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope
Peter J. Choi, Thomas Park, Elizabeth Cooper, et al.
Bioconjugate Chemistry (2020) Vol. 31, Iss. 7, pp. 1724-1739
Closed Access | Times Cited: 53
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
Filippo Torrisi, Nunzio Vicario, Federica Maria Spitale, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2860-2860
Open Access | Times Cited: 53
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda, Marta Domènech, Ainhoa Hernández, et al.
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 71-86
Open Access | Times Cited: 20
An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
Milan Teraiya, Hélène Perreault, Vincent Chen
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 20
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma
Daniel J. Laverty, Shiv K. Gupta, Gary A. Bradshaw, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer
Allison N. DuRoss, Madeleine Landry, Charles R. Thomas, et al.
Cancer Letters (2020) Vol. 500, pp. 208-219
Open Access | Times Cited: 50
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma
Chengchen Hu, Kimberly Wang, Ceylan Damon, et al.
Neuro-Oncology (2021) Vol. 24, Iss. 6, pp. 888-900
Open Access | Times Cited: 33
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 7, pp. 1338-1351
Closed Access | Times Cited: 15
Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence
Atanu Ghorai, Tejashree Mahaddalkar, Rahul Thorat, et al.
Cancer Letters (2020) Vol. 490, pp. 44-53
Closed Access | Times Cited: 39
The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices
Federica Di Cintio, Michele Dal Bo, Lorena Baboçi, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 36
The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
Anna Kirstein, Thomas E. Schmid, Stephanie E. Combs
Cancers (2020) Vol. 12, Iss. 5, pp. 1099-1099
Open Access | Times Cited: 34
Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes
Ramya Ambur Sankaranarayanan, Susanne Kossatz, Wolfgang Weber, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2130-2130
Open Access | Times Cited: 34
New Approaches to Glioblastoma
Mustafa Khasraw, Yoko Fujita, Catalina Lee-Chang, et al.
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 279-292
Open Access | Times Cited: 30
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
Ola Rominiyi, Spencer J. Collis
Molecular Oncology (2021) Vol. 16, Iss. 1, pp. 11-41
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top